541 reports of this reaction
2.0% of all LEVODOPA reports
#10 most reported adverse reaction
PRODUCT RESIDUE PRESENT is the #10 most commonly reported adverse reaction for LEVODOPA, manufactured by Merz Pharmaceuticals, LLC. There are 541 FDA adverse event reports linking LEVODOPA to PRODUCT RESIDUE PRESENT. This represents approximately 2.0% of all 26,727 adverse event reports for this drug.
Patients taking LEVODOPA who experience product residue present should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT RESIDUE PRESENT is a less commonly reported adverse event for LEVODOPA, but still significant enough to appear in the safety profile.
In addition to product residue present, the following adverse reactions have been reported for LEVODOPA:
PRODUCT RESIDUE PRESENT has been reported as an adverse event in 541 FDA reports for LEVODOPA. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT RESIDUE PRESENT accounts for approximately 2.0% of all adverse event reports for LEVODOPA, making it a notable side effect.
If you experience product residue present while taking LEVODOPA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.